Anne W Beaven
Overview
Explore the profile of Anne W Beaven including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
44
Citations
730
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Huang C, Wan Z, Niedzwiecki D, Prosnitz L, Beaven A, Kelsey C
Int J Radiat Oncol Biol Phys
. 2025 Feb;
PMID: 39993538
Purpose: Consolidation radiation therapy (RT) is often recommended in diffuse large B-cell lymphoma. The current recommended dose of 30 Gy was established in the pre-rituximab and PET-CT era. We hypothesized...
2.
Goyal A, OLeary D, Dabaja B, Weng W, Zain J, Cutler C, et al.
Transplant Cell Ther
. 2024 Sep;
30(11):1047-1060.
PMID: 39222792
Mycosis fungoides (MF) and Sézary syndrome (SS) are the most common subtypes of cutaneous T-cell lymphoma (CTCL). While MF generally follows an indolent course, a subset of patients will experience...
3.
Grover N, Hucks G, Riches M, Ivanova A, Moore D, Shea T, et al.
Lancet Haematol
. 2024 Mar;
11(5):e358-e367.
PMID: 38555923
Background: Chimeric antigen receptor (CAR) T cells targeting CD30 are safe and have promising activity when preceded by lymphodepleting chemotherapy. We aimed to determine the safety of anti-CD30 CAR T...
4.
5.
Grover N, Dittus C, Thakkar A, Beaven A
Hematology Am Soc Hematol Educ Program
. 2023 Dec;
2023(1):510-518.
PMID: 38066906
The treatment landscape of classical Hodgkin lymphoma has changed dramatically over the past decade. Relapsed and refractory mainstay therapeutics such as brentuximab vedotin (BV) and checkpoint inhibitors (CPIs) are being...
6.
Tschernia N, Heiling H, Deal A, Cheng C, Babinec C, Gonzalez M, et al.
J Immunother Cancer
. 2023 Aug;
11(8).
PMID: 37527906
Chimeric antigen receptor (CAR)-T cells targeting CD30 have demonstrated high response rates with durable remissions observed in a subset of patients with relapsed/refractory CD30+ hematologic malignancies, particularly classical Hodgkin lymphoma....
7.
Russell D, Byrd R, Googe P, Beaven A, Bowers E
JAAD Case Rep
. 2022 Feb;
21:66-69.
PMID: 35198702
No abstract available.
8.
Alderuccio J, Arcaini L, Watkins M, Beaven A, Shouse G, Epperla N, et al.
Blood Adv
. 2022 Feb;
6(7):2035-2044.
PMID: 35196377
Extranodal marginal zone lymphoma (EMZL) is a heterogeneous non-Hodgkin lymphoma. No consensus exists regarding the standard-of-care in patients with advanced-stage disease. Current recommendations are largely adapted from follicular lymphoma, for...
9.
Brem E, Li H, Beaven A, Caimi P, Cerchietti L, Alizadeh A, et al.
J Geriatr Oncol
. 2021 Oct;
13(2):258-264.
PMID: 34686472
Diffuse large B cell lymphoma (DLBCL) is an aggressive but potentially curable malignancy; however, cure is highly dependent on the ability to deliver intensive, anthracycline-based chemoimmunotherapy. Nearly one third of...
10.
Voorhees T, Zhao B, Oldan J, Hucks G, Khandani A, Dittus C, et al.
Blood Adv
. 2021 Oct;
6(4):1255-1263.
PMID: 34666347
Our group has recently demonstrated that chimeric antigen receptor T-cell therapy targeting the CD30 antigen (CD30.CAR-T) is highly effective in patients with relapsed and refractory (r/r) classical Hodgkin lymphoma (cHL)....